Splitting Hairs: New Drug Offers Hope for Baldness
Effective, government-approved treatment options for pattern hair loss have remained thin for decades, with the last approved medication dating back to 1997. However, the treatment landscape is on the verge of a major transformation.
Veradermics, a biopharmaceutical company based in New Haven, Connecticut, has announced positive Phase 3 clinical trial results for VDPHL01, a groundbreaking oral medication designed specifically for androgenetic alopecia (pattern hair loss in both men and women).
The new drug is an innovative oral formulation of minoxidil, the active ingredient famously used in topical treatments.
While immediate-release oral minoxidil has been used off-label by dermatologists since the 1970s, it carries cardiac risks by rapidly relaxing blood vessels and lowering blood pressure. To eliminate this issue, VDPHL01 utilises a proprietary hydrogel technology. This extended-release delivery system steadily releases the active ingredient over a longer period, safely exposing hair follicles to the drug without triggering dangerous blood pressure drops or excessive body hair growth.
Veradermics conducted a double-blind, six-month study that evaluated 519 men with mild-to-moderate hair loss. The results were highly encouraging: objective hair counts revealed that those taking the drug experienced four times as much regrowth as the placebo group, with visible changes detected by month two. The end of the trial saw nearly 80% of patients and investigators reporting significant improvement.
While Veradermics is currently recruiting for an additional trial to evaluate the drug’s efficacy in women, VDPHL01 is already positioned to become the first-ever oral hair loss treatment for female patients, bridging a massive gap in modern dermatology and comb out the competition.
